+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tuberculosis Testing Market - Global Forecast 2026-2032- Product Image
Tuberculosis Testing Market - Global Forecast 2026-2032- Product Image
Sale

Tuberculosis Testing Market - Global Forecast 2026-2032

  • Report

  • 187 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 4985927
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Tuberculosis Testing Market is projected to reach USD 2.49 Billion in 2026. It is expected to continue growing at a CAGR of 6.60%, reaching USD 3.68 Billion by 2032.

Tuberculosis testing is central to global TB control because timely diagnosis determines whether patients receive curative therapy, drug-resistance evaluation, and public health follow-up. According to the World Health Organization, an estimated 10.8 million people developed TB in 2023, and 1.25 million people died from the disease, underscoring the need for faster, more accessible diagnostic pathways.

The tuberculosis testing landscape spans tuberculin skin tests, interferon-gamma release assays, smear microscopy, culture, nucleic acid amplification tests, line probe assays, and urine lipoarabinomannan testing for eligible high-risk patients. Demand is being shaped by WHO recommendations favoring rapid molecular diagnostics as initial tests for symptomatic patients, rising drug-resistant TB surveillance needs, and expanded screening among vulnerable populations, including people living with HIV, household contacts, migrants, incarcerated populations, and individuals with diabetes or immunosuppression.

Transformative Shifts in the Tuberculosis Testing Landscape

The tuberculosis testing landscape is shifting from microscopy-led workflows toward rapid molecular testing, decentralized sample collection, and integrated drug-resistance detection. Culture remains essential for comprehensive susceptibility testing, but nucleic acid amplification tests can identify Mycobacterium tuberculosis and rifampicin resistance within hours, helping clinicians initiate appropriate treatment sooner and supporting public health teams in interrupting transmission.

Another major shift is the expansion of active case-finding beyond traditional clinics. Mobile chest X-ray, community sputum collection, digital reporting, contact investigation, and linkage-to-care platforms are improving detection in high-burden settings. These changes support national TB programs seeking to close the gap between estimated TB incidence and the number of people who are bacteriologically confirmed and notified, while also improving access for populations that face geographic, social, or economic barriers to facility-based diagnosis.

Cumulative Impact of Artificial Intelligence on TB Testing

Artificial intelligence is increasingly influencing tuberculosis testing through computer-aided detection for chest radiography, automated laboratory quality checks, workflow prioritization, and predictive outreach. WHO has stated that computer-aided detection software may be used as an alternative to human readers for TB screening and triage in people aged 15 years and older, when implemented with appropriate calibration and confirmatory testing.

AI does not replace microbiological confirmation, but it can accelerate screening, reduce reader variability, and support targeted testing in high-volume environments. The strongest use cases combine AI triage with WHO-recommended rapid molecular tests, laboratory information systems, and governance frameworks covering bias monitoring, data security, local validation, and clinical accountability. As digital chest radiography expands in community and mobile settings, AI-enabled triage is expected to remain most valuable where it shortens the pathway from symptom screening to confirmatory molecular diagnosis and treatment initiation.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific remains the largest burden environment for tuberculosis testing, led by high-incidence countries such as India, China, Indonesia, and the Philippines. The region is prioritizing rapid molecular diagnostics, private-sector notification, community screening, and drug-resistance detection to improve case finding and shorten time to treatment. Large population bases, diverse healthcare access levels, and national TB elimination strategies make Asia-Pacific a core region for molecular tuberculosis diagnostics, digital chest X-ray screening, and laboratory network strengthening.

North America and Europe are lower-incidence regions, but testing demand persists across migrants, people experiencing homelessness, correctional settings, healthcare workers, close contacts, and immunocompromised patients. In these regions, TB testing is closely linked to latent tuberculosis infection management, infection control, high-quality laboratory confirmation, and surveillance. Latin America faces urban transmission, access gaps, and uneven diagnostic capacity, creating a need for faster testing in underserved communities and stronger linkage-to-care systems. The Middle East has heterogeneous needs linked to migrant labor, border health, and national screening programs, while Africa carries a high TB and TB/HIV burden, making rapid molecular tests, urine LAM testing for eligible people with HIV, decentralized specimen referral, and integrated TB-HIV diagnostic services especially important.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN countries are expanding molecular tuberculosis testing, digital chest X-ray screening, and community-based case finding to address persistent transmission across high-burden and lower-burden member states. The GCC emphasizes workforce screening, migrant health protocols, centralized laboratory quality, and infection prevention in highly mobile populations. The European Union supports standardized surveillance, cross-border reporting, antimicrobial resistance monitoring, and latent TB infection management among risk groups, with testing strategies shaped by low-incidence elimination goals and migration-related health priorities.

BRICS countries represent a major share of the global TB burden and include several settings with substantial drug-resistant TB challenges, making the group critical to diagnostic adoption, local production, procurement scale, and national program implementation. G7 countries influence tuberculosis testing through innovation funding, regulatory expectations, global health financing, laboratory standards, and support for high-burden countries. NATO members focus on resilient healthcare systems, military readiness, outbreak preparedness, and infectious disease surveillance that includes TB risk management for deployed personnel, mobile populations, and vulnerable communities.

Key Country Insights Across Major Tuberculosis Testing Markets

The United States and Canada maintain low TB incidence but rely on targeted testing, contact investigations, and latent TB screening among higher-risk populations, including people born in countries with higher TB burden, individuals with HIV, and immunocompromised patients. Mexico and Brazil face larger public health needs, with molecular diagnostics supporting earlier detection in urban, remote, and underserved communities. The United Kingdom, Germany, France, Italy, and Spain emphasize migrant screening, laboratory quality, contact tracing, and latent TB prevention, while Russia remains a priority country for multidrug-resistant and rifampicin-resistant TB diagnostics due to its documented drug-resistant TB burden.

China and India are pivotal due to population scale, national TB elimination strategies, and rapid test deployment across public health networks. India continues to expand molecular testing, private-sector engagement, and active case-finding initiatives, while China combines surveillance, laboratory modernization, and targeted screening in high-risk groups. Japan, Australia, and South Korea combine low-incidence surveillance with advanced laboratory networks, rigorous contact investigation, and targeted latent TB testing. Across these countries, the strongest opportunities are linked to rapid molecular testing, culture and drug-susceptibility testing, digital notification, specimen referral systems, AI-assisted radiology screening, and programs that connect diagnosis to treatment initiation without delay.

Actionable Recommendations for Tuberculosis Testing Industry Leaders

Industry leaders should align product portfolios with WHO-recommended diagnostic algorithms, especially rapid molecular tests that detect TB and key drug-resistance markers. Commercial strategies should prioritize affordability, cartridge availability, instrument uptime, biosafety, specimen logistics, and service models that work in centralized laboratories, district hospitals, mobile screening programs, and decentralized care settings.

Organizations should also invest in interoperable digital reporting, external quality assurance, sample transport, maintenance networks, and AI-enabled screening partnerships. The most defensible strategies will combine validated diagnostics with training, supply continuity, local regulatory engagement, and evidence generation that demonstrates improved case detection, faster treatment initiation, stronger drug-resistance surveillance, and reduced loss to follow-up. Partnerships with public health programs should focus on workflow integration, not only test placement, so that screening, confirmation, reporting, and treatment linkage operate as a single patient-centered pathway.

Research Methodology

This executive summary is based on a structured review of authoritative public health and scientific sources, including WHO guidance, national TB program priorities, CDC and ECDC materials, peer-reviewed diagnostic evidence, regulatory trends, and publicly available health policy information. Insights were triangulated across disease burden, testing algorithms, procurement patterns, diagnostic technology adoption, screening guidance, and laboratory implementation signals.

The methodology emphasizes verified, data-backed interpretation rather than unsupported estimates. Regional, group, and country insights were assessed through the lens of TB incidence, drug-resistant TB burden, TB/HIV co-infection, laboratory capacity, reimbursement conditions, screening policies, and the practical role of molecular diagnostics, culture, immunological testing, urine LAM testing, and AI-assisted radiology. The analysis excludes market sizing, market share, and forecasting, focusing instead on evidence-based shifts in tuberculosis testing access, clinical utility, and public health relevance.

Conclusion

Tuberculosis testing is moving toward faster, more connected, and more patient-centered diagnostic models. The combination of rapid molecular testing, targeted screening, drug-resistance detection, AI-supported triage, and digital linkage-to-care is becoming essential for national TB programs and healthcare providers aiming to reduce transmission, improve treatment outcomes, and address persistent diagnostic gaps.

For industry participants, the opportunity is not limited to test placement. Long-term value will come from reliable access, operational support, data integration, quality assurance, and evidence-based partnerships that help close diagnostic gaps in high-burden countries while maintaining surveillance strength in low-incidence markets. Organizations that support complete diagnostic pathways-from screening and confirmatory testing to reporting and treatment initiation-will be best positioned to contribute to global TB elimination priorities.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Tuberculosis Testing Market, by Test Type
7.1. Introduction
7.2. Culture Test
7.2.1. Liquid Culture
7.2.2. Solid Culture
7.3. Immunological Test
7.3.1. Elisa
7.3.2. Western Blot
7.4. Molecular Test
7.4.1. Line Probe Assay
7.4.2. Pcr
7.5. Rapid Diagnostic Test
7.5.1. Chromatographic
7.5.2. Lateral Flow
8. Tuberculosis Testing Market, by Technology
8.1. Introduction
8.2. Culture Based Technology
8.3. Immunodiagnostic
8.4. Lipoarabinomannan Assay
8.5. Nucleic Acid Amplification Test
9. Tuberculosis Testing Market, by Sample Type
9.1. Introduction
9.2. Blood
9.3. Sputum
9.4. Urine
10. Tuberculosis Testing Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Hospitals
10.4. Reference Laboratory
11. Tuberculosis Testing Market, by Distribution Channel
11.1. Introduction
11.2. Diagnostic Laboratory
11.3. Hospital Pharmacy
11.4. Online Pharmacy
12. Tuberculosis Testing Market, by Application
12.1. Introduction
12.2. Active Tuberculosis
12.3. Latent Tuberculosis
13. Tuberculosis Testing Market, by Region
13.1. Asia-Pacific
13.2. North America
13.3. Latin America
13.4. Europe
13.5. Middle East
13.6. Africa
14. Tuberculosis Testing Market, by Group
14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO
15. Tuberculosis Testing Market, by Country
15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea
16. Competitive Landscape
16.1. Market Share Analysis, 2025
16.2. FPNV Positioning Matrix, 2025
16.3. Market Concentration Analysis, 2025
16.3.1. Concentration Ratio (CR)
16.3.2. Herfindahl Hirschman Index (HHI)
16.4. Recent Developments & Impact Analysis, 2025
16.5. Product Portfolio Analysis, 2025
16.6. Benchmarking Analysis, 2025
17. Company Profiles
17.1. Abbott Laboratories
17.2. Becton, Dickinson and Company
17.3. Bio-Rad Laboratories, Inc.
17.4. Biocartis Group NV
17.5. bioMérieux SA
17.6. Bruker Corporation.
17.7. Creative Diagnostics
17.8. Danaher Corporation
17.9. DiaSorin S.p.A.
17.10. F. Hoffmann-La Roche Ltd.
17.11. Fujifilm Holdings Corporation
17.12. Hologic, Inc.
17.13. Kindstar Globalgene Technology, Inc.
17.14. Lionex GmbH
17.15. Molbio Diagnostics Limited
17.16. QIAGEN N.V.
17.17. Revvity, Inc.
17.18. SD Biosensor, Inc.
17.19. Seegene Inc.
17.20. Siemens Healthineers AG
17.21. Thermo Fisher Scientific Inc.
17.22. Zhejiang Di'an Diagnostics Technology Co., Ltd.
List of Figures
FIGURE 1. GLOBAL TUBERCULOSIS TESTING MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL TUBERCULOSIS TESTING MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL TUBERCULOSIS TESTING MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL TUBERCULOSIS TESTING MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
FIGURE 7. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
FIGURE 9. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 13. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 15. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
FIGURE 17. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 19. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 23. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL TUBERCULOSIS TESTING MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 25. GLOBAL TUBERCULOSIS TESTING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL TUBERCULOSIS TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL CULTURE TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL CULTURE TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL CULTURE TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL LIQUID CULTURE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL LIQUID CULTURE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL LIQUID CULTURE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL SOLID CULTURE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL SOLID CULTURE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL SOLID CULTURE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL IMMUNOLOGICAL TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL IMMUNOLOGICAL TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL IMMUNOLOGICAL TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL ELISA MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL ELISA MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL ELISA MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL WESTERN BLOT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL WESTERN BLOT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL WESTERN BLOT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL MOLECULAR TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL MOLECULAR TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL MOLECULAR TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL LINE PROBE ASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL LINE PROBE ASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL LINE PROBE ASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL PCR MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL PCR MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL PCR MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL RAPID DIAGNOSTIC TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL RAPID DIAGNOSTIC TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL RAPID DIAGNOSTIC TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL CHROMATOGRAPHIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL CHROMATOGRAPHIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL CHROMATOGRAPHIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL LATERAL FLOW MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL LATERAL FLOW MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL LATERAL FLOW MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL CULTURE BASED TECHNOLOGY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL CULTURE BASED TECHNOLOGY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL CULTURE BASED TECHNOLOGY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL IMMUNODIAGNOSTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL IMMUNODIAGNOSTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL IMMUNODIAGNOSTIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL LIPOARABINOMANNAN ASSAY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL LIPOARABINOMANNAN ASSAY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL LIPOARABINOMANNAN ASSAY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL NUCLEIC ACID AMPLIFICATION TEST MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL NUCLEIC ACID AMPLIFICATION TEST MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL NUCLEIC ACID AMPLIFICATION TEST MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL BLOOD MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL SPUTUM MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL SPUTUM MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL SPUTUM MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL URINE MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL URINE MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL REFERENCE LABORATORY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL REFERENCE LABORATORY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL REFERENCE LABORATORY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL DIAGNOSTIC LABORATORY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL DIAGNOSTIC LABORATORY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL DIAGNOSTIC LABORATORY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL HOSPITAL PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL ONLINE PHARMACY MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL ONLINE PHARMACY MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL ONLINE PHARMACY MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL ACTIVE TUBERCULOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL ACTIVE TUBERCULOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL ACTIVE TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL LATENT TUBERCULOSIS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL LATENT TUBERCULOSIS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL LATENT TUBERCULOSIS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 91. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 93. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2017-2032 (USD MILLION)
TABLE 94. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2017-2032 (USD MILLION)
TABLE 95. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 96. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2017-2032 (USD MILLION)
TABLE 97. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 98. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 99. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 100. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 101. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 102. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 103. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 104. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2017-2032 (USD MILLION)
TABLE 105. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2017-2032 (USD MILLION)
TABLE 106. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 107. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2017-2032 (USD MILLION)
TABLE 108. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 109. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 110. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 111. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 112. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 113. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 114. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 115. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2017-2032 (USD MILLION)
TABLE 116. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2017-2032 (USD MILLION)
TABLE 117. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 118. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2017-2032 (USD MILLION)
TABLE 119. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 120. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 121. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 122. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 123. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 124. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 125. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 126. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2017-2032 (USD MILLION)
TABLE 127. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2017-2032 (USD MILLION)
TABLE 128. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 129. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2017-2032 (USD MILLION)
TABLE 130. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 131. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 132. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 133. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 134. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 135. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 136. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 137. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2017-2032 (USD MILLION)
TABLE 138. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2017-2032 (USD MILLION)
TABLE 139. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 140. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2017-2032 (USD MILLION)
TABLE 141. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 142. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 143. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 144. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 145. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 146. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 147. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 148. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2017-2032 (USD MILLION)
TABLE 149. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2017-2032 (USD MILLION)
TABLE 150. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 151. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2017-2032 (USD MILLION)
TABLE 152. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 153. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 154. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 155. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 156. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 157. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 158. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 159. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 160. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2017-2032 (USD MILLION)
TABLE 161. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2017-2032 (USD MILLION)
TABLE 162. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 163. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2017-2032 (USD MILLION)
TABLE 164. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 165. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 166. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 167. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 168. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 169. GCC TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 170. GCC TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 171. GCC TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2017-2032 (USD MILLION)
TABLE 172. GCC TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2017-2032 (USD MILLION)
TABLE 173. GCC TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 174. GCC TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2017-2032 (USD MILLION)
TABLE 175. GCC TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 176. GCC TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 177. GCC TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 178. GCC TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 179. GCC TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 180. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 181. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 182. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2017-2032 (USD MILLION)
TABLE 183. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2017-2032 (USD MILLION)
TABLE 184. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 185. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2017-2032 (USD MILLION)
TABLE 186. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 187. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 188. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 189. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 190. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 191. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 192. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 193. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2017-2032 (USD MILLION)
TABLE 194. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2017-2032 (USD MILLION)
TABLE 195. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 196. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2017-2032 (USD MILLION)
TABLE 197. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 198. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 199. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 200. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 201. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 202. G7 TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 203. G7 TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 204. G7 TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2017-2032 (USD MILLION)
TABLE 205. G7 TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2017-2032 (USD MILLION)
TABLE 206. G7 TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 207. G7 TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2017-2032 (USD MILLION)
TABLE 208. G7 TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 209. G7 TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 210. G7 TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 211. G7 TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 212. G7 TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 213. NATO TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 214. NATO TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 215. NATO TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2017-2032 (USD MILLION)
TABLE 216. NATO TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2017-2032 (USD MILLION)
TABLE 217. NATO TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 218. NATO TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2017-2032 (USD MILLION)
TABLE 219. NATO TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 220. NATO TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 221. NATO TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 222. NATO TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 223. NATO TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 224. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 225. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 226. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 227. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2017-2032 (USD MILLION)
TABLE 228. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2017-2032 (USD MILLION)
TABLE 229. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 230. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2017-2032 (USD MILLION)
TABLE 231. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 232. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 233. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 234. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 235. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 236. CANADA TUBERCULOSIS TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 237. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 238. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2017-2032 (USD MILLION)
TABLE 239. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2017-2032 (USD MILLION)
TABLE 240. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 241. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2017-2032 (USD MILLION)
TABLE 242. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 243. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 244. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 245. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 246. CANADA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 247. MEXICO TUBERCULOSIS TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 248. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 249. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2017-2032 (USD MILLION)
TABLE 250. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2017-2032 (USD MILLION)
TABLE 251. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 252. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2017-2032 (USD MILLION)
TABLE 253. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 254. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 255. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 256. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 257. MEXICO TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 258. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 259. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 260. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2017-2032 (USD MILLION)
TABLE 261. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2017-2032 (USD MILLION)
TABLE 262. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 263. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2017-2032 (USD MILLION)
TABLE 264. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 265. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 266. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 267. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 268. BRAZIL TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 269. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 270. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 271. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2017-2032 (USD MILLION)
TABLE 272. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2017-2032 (USD MILLION)
TABLE 273. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 274. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2017-2032 (USD MILLION)
TABLE 275. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 276. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 277. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 278. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 279. UNITED KINGDOM TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 280. GERMANY TUBERCULOSIS TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 281. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 282. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2017-2032 (USD MILLION)
TABLE 283. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2017-2032 (USD MILLION)
TABLE 284. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 285. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2017-2032 (USD MILLION)
TABLE 286. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 287. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 288. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 289. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 290. GERMANY TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 291. FRANCE TUBERCULOSIS TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 292. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 293. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2017-2032 (USD MILLION)
TABLE 294. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2017-2032 (USD MILLION)
TABLE 295. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 296. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2017-2032 (USD MILLION)
TABLE 297. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 298. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 299. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 300. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 301. FRANCE TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 302. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 303. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 304. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2017-2032 (USD MILLION)
TABLE 305. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2017-2032 (USD MILLION)
TABLE 306. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 307. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2017-2032 (USD MILLION)
TABLE 308. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 309. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 310. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 311. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 312. RUSSIA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 313. ITALY TUBERCULOSIS TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 314. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 315. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2017-2032 (USD MILLION)
TABLE 316. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2017-2032 (USD MILLION)
TABLE 317. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 318. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2017-2032 (USD MILLION)
TABLE 319. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 320. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 321. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 322. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 323. ITALY TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 324. SPAIN TUBERCULOSIS TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 325. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 326. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2017-2032 (USD MILLION)
TABLE 327. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2017-2032 (USD MILLION)
TABLE 328. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 329. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2017-2032 (USD MILLION)
TABLE 330. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 331. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 332. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 333. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 334. SPAIN TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 335. CHINA TUBERCULOSIS TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 336. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 337. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2017-2032 (USD MILLION)
TABLE 338. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2017-2032 (USD MILLION)
TABLE 339. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 340. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2017-2032 (USD MILLION)
TABLE 341. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 342. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 343. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 344. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 345. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 346. INDIA TUBERCULOSIS TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 347. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 348. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2017-2032 (USD MILLION)
TABLE 349. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2017-2032 (USD MILLION)
TABLE 350. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2017-2032 (USD MILLION)
TABLE 351. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2017-2032 (USD MILLION)
TABLE 352. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2017-2032 (USD MILLION)
TABLE 353. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2017-2032 (USD MILLION)
TABLE 354. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 355. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 356. INDIA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2017-2032 (USD MILLION)
TABLE 357. JAPAN TUBERCULOSIS TESTING MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 358. JAPAN TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2017-2032 (USD MILLION)
TABLE 359. JAPAN TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2017-2032 (USD MILLION)
TABLE 360. JAPAN TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST

Companies Mentioned

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Biocartis Group NV
  • bioMérieux SA
  • Bruker Corporation.
  • Creative Diagnostics
  • Danaher Corporation
  • DiaSorin S.p.A.
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • Hologic, Inc.
  • Kindstar Globalgene Technology, Inc.
  • Lionex GmbH
  • Molbio Diagnostics Limited
  • QIAGEN N.V.
  • Revvity, Inc.
  • SD Biosensor, Inc.
  • Seegene Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Zhejiang Di'an Diagnostics Technology Co., Ltd.

Table Information

Report AttributeDetails
No. of Pages187
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 2.49 Billion
Forecasted Market Value ( USD ) by 2032 $ 3.68 Billion
Compound Annual Growth Rate6.6%
Regions CoveredGlobal
No. of Companies Mentioned22

Related Topics

Related Reports

Tuberculosis Diagnostics Market - Global Forecast 2026-2032 - Product Image

Tuberculosis Diagnostics Market - Global Forecast 2026-2032

  • Report
  • 197 Pages
  • Global
From
Tuberculosis Diagnostics Market Size, Share, Trends and Forecast by Disease Stage, Test Type, End-User, and Region, 2026-2034 - Product Image

Tuberculosis Diagnostics Market Size, Share, Trends and Forecast by Disease Stage, Test Type, End-User, and Region, 2026-2034

  • Report
  • 137 Pages
  • Global
From
Tuberculosis Diagnostics - Global Strategic Business Report - Product Image

Tuberculosis Diagnostics - Global Strategic Business Report

  • Report
  • 284 Pages
  • Global
From
Tuberculosis Testing - Global Strategic Business Report - Product Image

Tuberculosis Testing - Global Strategic Business Report

  • Report
  • 423 Pages
  • Global
From
Tuberculosis Diagnostics Market Report 2026 - Product Image

Tuberculosis Diagnostics Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Tuberculosis Test Market

The Tuberculosis Test market is a subset of the larger Infectious Disease Testing market. It is used to detect the presence of Mycobacterium tuberculosis, the bacteria that causes tuberculosis. Tests are used to diagnose active tuberculosis, as well as to monitor the effectiveness of treatment. Tests can be divided into two categories: those that detect the presence of the bacteria, and those that detect the body's immune response to the bacteria. The most common tests are the tuberculin skin test, the interferon-gamma release assay, and the nucleic acid amplification test. The Tuberculosis Test market is highly competitive, with many companies offering a variety of tests. Some of the major players in the market include Abbott Laboratories, Becton Dickinson, Cepheid, Hologic, and Roche Diagnostics. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.